Miro clears TGA audit ahead of Crohn’s disease trial

The Sydney Morning Herald - Nov 12, 2026

Miro Sciences has cleared a TGA manufacturing hurdle for its Crohn’s trial, with the regulator inspecting its partner’s facility ahead of a planned Phase 2 study for its StemSmart cell therapy.

Read full article

More News

The Morning Herald

The Morning Herald is a fast news provider in the United States since 2005. Fiercely independent and armed with irreverent intelligence, there’s no other place to get your news other than The Morning Herald.

NEWSLETTER